Compare Amgen, Inc. (AMGN) vs Oscar Health Inc (OSCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Oscar Health Inc — how do they compare? Amgen, Inc. trades at $366.75 (market cap $196.12B), while Oscar Health Inc trades at $30.32 (market cap $9.21B). The key difference: Amgen, Inc. is far larger — about 21.3× Oscar Health Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| AMGN | OSCR | |
|---|---|---|
Market Cap | $196.12B | $9.21B |
Sector | Health | Health |
52-Week High | $388.16 | $32.18 |
52-Week Low | $271.18 | $10.85 |
Enterprise Value | $241.41B | $4.83B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
OSCR trades at $30.54, down 2.12% today but up significantly year-to-date. Technicals are bullish with moving averages supporting the uptrend, while oscillators show neutral momentum. Fundamentally, revenue grew to $11.70B in 2025 with a net loss of $443M, but 2026 guidance projects improved profitability. Recent news highlights strong Q1 2026 earnings beat and reaffirmed growth targets at industry conferences.
Outlook remains optimistic due to strong revenue growth and operational improvements, but risks include persistent net losses and competitive pressures. Analyst consensus is mixed with a $22.50 price target below current levels, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
